Table 3 Reasons for interruption of darunavir/cobicistat
Dual therapy | Triple therapy | Total | ||||
|---|---|---|---|---|---|---|
N = 72 | % | N = 177 | % | N = 249 | % | |
Adverse events | 1 | 1.4 | 12 | 6.8 | 13 | 5.2 |
Simplification/proactive switch | 1 | 1.4 | 14 | 7.9 | 15 | 6.0 |
Patient’s preference/low adherence | 2 | 2.8 | 6 | 3.4 | 8 | 3.2 |
Therapeutic failure | 2 | 2.8 | 0 | 0.0 | 2 | 0.8 |
Death | 0 | 0.0 | 2 | 1.1 | 2 | 0.8 |
Drug-drug interaction | 1 | 1.4 | 3 | 1.7 | 4 | 1.6 |
Other reasons | 1 | 1.4 | 1 | 0.6 | 2 | 0.8 |
Lost to follow-up | 8 | 11.1 | 18 | 10.2 | 26 | 10.4 |